H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Celldex (CLDX) to $50 from $80 and keeps a Buy rating on the shares following the Q1 report. The firm expects 2025 to be a year of continued execution across the company’s pipeline, and highlight the current status of the ongoing programs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- Celldex’s Promising Pipeline and Strong Financial Position Justify Buy Rating
- Celldex reports Q1 EPS (81c), consensus (74c)
- Optimistic Buy Rating for Celldex Driven by Promising Barzolvolimab Developments and Strong Financial Position
- Promising Phase 2 Results for Celldex’s Barzolvolimab in Eosinophilic Esophagitis Boosts Buy Rating
- Celldex presents histology data from barzolvolimab study